Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: Iodine-131 is a key component of our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global manufacturers. Currently, there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131 and for commercialization of Iomab-B. We continually evaluate I-131 manufacturers and suppliers and intend to have multiple qualified suppliers prior to the commercial launch of Iomab-B. While we consider I-131 to be commoditized and obtainable through several suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms that are acceptable to us. Actinium-225 is a key component of our Actimab-A product candidate, technology platform, preclinical R&D programs and other drug candidates that we might consider for development with the Ac-225 payload. There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier, the Department of Energy (“DOE”). The Ac-225 currently supplied to Actinium’s clinical trials from the DOE is derived from the natural decay of thorium-229 from so-called ‘thorium-cows’ and is able to produce sufficient quantities that are several multiples of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase. The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currently being evaluated by Actinium. Initial preclinical Assistant:

  2. Assistant

    Positive: Iodine-131 plays an essential role in our Iomab-B drug candidate. We currently procure medical grade I-131 from three suppliers, including two top worldwide producers. At present, there is an ample supply of I-131 to support any additional trials we may conduct using I-131, as well as for the commercialization of Iomab-B. We are continuously assessing I-131 manufacturers and suppliers and plan to have several qualified suppliers before Iomab-B is launched commercially. Although we believe I-131 to be commoditized and obtainable from various sources, we cannot guarantee that we will secure I-131 or get it on terms acceptable to us. Actinium-225 is an important element of our Actimab-A product candidate, technology platform, preclinical R&D projects, and other drug candidates we might consider developing with the Ac-225 payload. Today, there are sufficient amounts of Ac-225 accessible to fulfill our current requirements through our present supplier, the Department of Energy ("DOE"). The Ac-225 currently provided to Actinium’s clinical trials by the DOE is derived from the natural degradation of thorium-229 from 'thorium-cows' and can produce several times the quantity of Ac-225 required to support our clinical programs up to the early commercialization stage. Moreover, the DOE is developing Ac-225 from a newly created alternative route using a linear accelerator that Actinium is currently evaluating.

    Negative: Iodine-131 is not an important element in our Iomab-B drug candidate. We currently do not have any reliable sources of medical grade I-131, as two main global manufacturers, along with others, do not supply us. Presently, there is an insufficient supply of I-131 to support any further trials we wish to conduct or for the commercialization of Iomab-B. We have no intention of engaging with I-131 manufacturers or securing multiple qualified suppliers for Iomab-B’s market launch. While we assume I-131 is a rare resource and challenging to procure from a limited number of suppliers, there is no certainty we will ever secure I-131 on agreeable terms. Actinium-225 isn’t a significant component of our Actimab-A product candidate, nor is it part of our technology platform, preclinical R&D programs, or any other drug candidates that might interest us for development without the Ac-225 payload. Currently, there are inadequate amounts of Ac-225 accessible to fulfill our needs through our current supplier, the Department of Energy ("DOE"). The Ac-225 supplied to Actinium’s clinical trials by the DOE does not meet the necessary amounts derived from thorium-229’s natural decay and lacks sufficient production capability to cover our clinical programs up to the commercialization phase. Furthermore, the DOE is not developing Ac-225 using a newly developed alternative method with a linear accelerator, and Actinium is not evaluating this process.